Recognizing off-target drug effects in the gut and brain: revisiting isotretinoin and depression

2015 ◽  
Vol 41 (3) ◽  
pp. 283-284 ◽  
Author(s):  
R. Kollipara ◽  
C. Reisz
Keyword(s):  
Drug Effects ◽  
Target Drug

Abstract 4907: Elucidating the role of retroactive signaling and kinase inhibitors on off-target drug effects

2011 ◽  
Author(s):  
Michelle L. Wynn ◽  
Alejandra C. Ventura ◽  
Hector Garcia ◽  
Jacques-A. Sepulchre ◽  
Sofia D. Merajver
Keyword(s):  
Kinase Inhibitors ◽  
Drug Effects ◽  
Target Drug

scholarly journals PREDICTION OF OFF-TARGET DRUG EFFECTS THROUGH DATA FUSION

2013 ◽  
Author(s):  
EMMANUEL R. YERA ◽  
ANN E. CLEVES ◽  
AJAY N. JAIN
Keyword(s):  
Data Fusion ◽  
Drug Effects ◽  
Target Drug

scholarly journals Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software

2019 ◽  
Vol 92 (2) ◽  
pp. 1856-1864 ◽  
Author(s):  
Cong-Hui Yao ◽  
Lingjue Wang ◽  
Ethan Stancliffe ◽  
Miriam Sindelar ◽  
Kevin Cho ◽  
...  
Keyword(s):  
Dose Response ◽  
Drug Effects ◽  
Target Drug ◽  
Biochemical Mechanisms

scholarly journals The zebrafish embryo as a model for assessing off-target drug effects

2010 ◽  
Vol 3 (11-12) ◽  
pp. 689-692 ◽  
Author(s):  
U. Strahle ◽  
C. Grabher
Keyword(s):  
Zebrafish Embryo ◽  
Drug Effects ◽  
Target Drug

Off-Target drug effects resulting in altered gene expression events with epigenetic and ⿿Quasi-Epigenetic⿿ origins

2016 ◽  
Vol 107 ◽  
pp. 229-233 ◽  
Author(s):  
Stephen J. Anderson ◽  
Kristina M. Feye ◽  
Garrett R. Schmidt-McCormack ◽  
Emir Malovic ◽  
Gregory S.A. Mlynarczyk ◽  
...  
Keyword(s):  
Gene Expression ◽  
Drug Effects ◽  
Altered Gene Expression ◽  
Target Drug ◽  
Altered Gene

Abstract 2012: Off-target drug effects due to retroactivity in signaling pathways

2010 ◽  
Author(s):  
Michelle Wynn ◽  
Alejandra Ventura ◽  
Hector Garcia ◽  
Sofia Merajver
Keyword(s):  
Signaling Pathways ◽  
Drug Effects ◽  
Target Drug

scholarly journals Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review

2020 ◽  
Vol 21 (11) ◽  
pp. 4154 ◽  
Author(s):  
Julian Matthias Metzler ◽  
Laurin Burla ◽  
Daniel Fink ◽  
Patrick Imesch
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Drug Effects ◽  
Suppressor Cells ◽  
T Cell Response ◽  
Target Drug ◽  
Gynecological Malignancies ◽  
Programmed Death ◽  
Cancer Studies

Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development. It is FDA approved for the treatment of certain hematological malignancies. Several promising off-target drug effects have led to multiple, mostly preclinical investigations regarding its use in solid tumors. Unfortunately, data on its effectiveness in gynecological malignancies are limited, and (systematic) reviews are missing. The objective of this review was to summarize the existing literature and to analyze the evidence of ibrutinib as a treatment option in gynecological malignancies, including breast cancer. Studies were identified in MEDLINE and EMBASE using a defined search strategy, and preclinical or clinical research projects investigating ibrutinib in connection with these malignancies were considered eligible for inclusion. Our findings showed that preclinical studies generally confirm ibrutinib’s efficacy in cell lines and animal models of ovarian, breast, and endometrial cancer. Ibrutinib exerts multiple antineoplastic effects, such as on-target BTK inhibition, off-target kinase inhibition, and immunomodulation by interference with myeloid-derived suppressor cells (MDSCs), programmed death-ligand 1 (PD-L1), and T cell response. These mechanisms were elaborated and discussed in the context of the evidence available. Further research is needed in order to transfer the preclinical results to a broader clinical appliance.

Sign in / Sign up

Export Citation Format

Share Document